References
- Tysnes OB, Storstein A. Epidemiology of Parkinson’s disease. J Neural Transm (Vienna). 2017;124(8):901–905.
- GBD 2016. Parkinson’s disease collaborators. Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2018;17(11):939–953.
- Parkinson J. An essay on the shaking palsy. London: sherwood, Neely and Jones; 1817; republished as Parkinson J. An essay on the shaking palsy. J Neuropsychiatry Clin Neurosci. 2002;14(2):223–236.
- Galvan A, Wichmann T. Pathophysiology of Parkinsonism. Clin Neurophysiol. 2018;119(7):1459–1474.
- Poewe W, Mahlknet P. The clinical progression of Parkinson’s disease. Parkinsonism Relat Disord. 2009;15:S24–S27.
- Chaudhuri KR, Healy DG, Schapira AHV. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet. 2006;5(3):235–245.
- Comi C, Magistrelli L, Oggioni GD, et al. Peripheral nervous system involvement in Parkinson’s disease: evidence and controversies. Parkinsonism Relat Disord. 2014;20(12):1329–1334.
- Carlsson A. The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol Rev. 1959;11:490–493.
- Birkmayer W, The L-dihydroxyphenylalanine HO. (L-DOPA) effect in Parkinson’s syndrome in Man: on the Pathogenesis and treatment of Parkinson akinesis. Arch Psychiatr Nervenkr Z Gesamte Neurol Psychiatr. 1962;203:560–574.
- Salvati P, Maj R, Caccia C, et al. Biochemical and electrophysiological studies on the mechanism of action of PNU-151774E, a novel antiepileptic compound. J Pharmacol Exp Ther. 1999;288(3):1151–1159.
- Grondin R, Bédard PJ, Hadj Tahar A, et al. Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys. Neurology. 1999;52(8):1673–1677.
- The FS. 200-year journey of Parkinson disease: reflecting on the past and looking towards the future. Parkinsonism Relat Disord. 2018;46(Suppl 1):S1–S5.
- Spillantini MG, Schmidt ML, Lee VM, et al. Alpha-synuclein in lewy bodies. Nature. 1997;388(6645):839–840.
- Burré J. The synaptic function of α-Synuclein. J Parkinsons Dis. 2015;5(4):699–713.
- Axelsen TM, Woldbye DPD. Gene therapy for Parkinson’s disease, an update. J Parkinsons Dis. 2018;8(2):195–215.
- Fan Y, Winanto NSY. Replacing what’s lost: a new era of stem cell therapy for Parkinson’s disease. Transl Neurodegener. 2020;9:2. Published 2020 Jan 7.
- Davis AA, Leyns CEG, Holtzman DM. Intercellular spread of protein aggregates in neurodegenerative disease. Annu Rev Cell Dev Biol. 2018;34:545–568.
- Dettmer U, Selkoe D, Bartels T. New insights into cellular α-synuclein homeostasis in health and disease. Curr Opin Neurobiol. 2016;36:15–22.
- Zhang G, Xia Y, Wan F, et al. New perspectives on roles of alpha-synuclein in Parkinson’s disease. Front Aging Neurosci. 2018;10:370.
- AC immune pipeline. [cited 2020 April 28]. Available from: https://www.acimmune.com/en/pipeline-overview/
- Primary peptides pipeline. [cited 2020 April 28]. Available from: https://www.primarypeptides.com/research/product-pipeline/
- Sangamo pipeline. [cited 2020 April 28]. Available from: https://www.sangamo.com/pipeline
- A novel scFv antibody fragment to misfolded alpha synuclein as a potent modulator of neuroinflammation by in vivo intransal delivery. Presented at 11th Annual PEGS Europe; Lisbon. Available from: http://www.giiconference.com/chi809127/phage-display.shtml
- Funds will be used to advance Axial’s gut-targeted programs in Parkinson’s disease and autism spectrum disorder. [cited 2020 Apr 28]. Availabe from: https://www.axialbiotherapeutics.com/2019/02/axial-biotherapeutics-raises-25-million-in-series-b-financing/
- Seelos therapeutics pipeline. [cited 2020 Apr 28]. Available from: https://seelostherapeutics.com/sls-007/
- TauRX pipeline. [cited 2020 Apr 28]. Available from: https://taurx.com/pipeline.html
- Capo therapeutics pipeline. [cited 2020 Apr 28]. Available from: http://capotherapeutics.com/vaccine-pipeline/
- BioArctic Pipeline. [cited 2020 Apr 28]. Available from: https://www.bioarctic.se/en/project-portfolio-1921/Last
- ABL bio pipeline. [cited 2020 Apr 28]. Available from: http://ablbio.com/en/company/about
- Gismo therapeutics pipeline. [cited 2020 Apr 28]. Available from: http://gismotherapeutics.com/science/Lat
- Fulcrum therapeutics pipeline. [cited 2020 Apr 28]. Available from: https://www.fulcrumtx.com/pipeline/
- Priavoid pipeline. [cited 2020 Apr 28]. Available from: https://priavoid.com/pipeline/Last
- Yan R, Zhang J, Park HJ, et al. Synergistic neuroprotection by coffee components eicosanoyl-5-hydroxytryptamide and caffeine in models of Parkinson’s disease and DLB. Proc Natl Acad Sci U S A. 2018;115(51):E12053–E12062.
- Treventis pipeline. [cited 2020 Apr 28]. Available from: https://treventis.com/pipeline/
- Prosetta Bioscience pipeline. [cited 2020 Apr 28]. Available from: https://www.prosetta.com/parkinsons-program
- ProMIS neuroscience pipeline. [cited 2020 Apr 28]. Available from: https://promisneurosciences.com/product-portfolio
- Arvinas pipeline. [cited 2020 Apr 28]. Available from: https://www.arvinas.com/pipeline-programs/neurodegeneration-next-generation-targets
- Immungenetics pipeline. [cited 2020 Apr 28]. Available from: https://www.immungeneticsag.com/pipeline/
- United neuroscience pipeline. [cited 2020 Apr 28]. Available from: https://www.unitedneuroscience.com/pipeline
- Proclara bio pipeline. [cited 2020 Apr 28]. Available from: http://www.proclarabio.com/our-programs
- Kuo YM, Nwankwo EI, Nussbaum RL, et al. Translational inhibition of α-synuclein by Posiphen normalizes distal colon motility in transgenic Parkinson mice. Am J Neurodegener Dis. 2019;8(1):1–15. Published 2019 Feb 15.
- Yumanity therapeutics initiates phase 1 clinical trial of lead candidate YTX-7739 for the treatment of Parkinson’s disease. [cited 2020 Apr 28]. Available from: http://www.yumanity.com/wp-content/uploads/2019/10/Yumanity_Phase-1-Trial-Initiation_Press-Release_FINAL.pdf
- Alarcón-Arís D, Recasens A, Galofré M, et al. Selective α-Synuclein knockdown in monoamine neurons by intranasal oligonucleotide delivery: potential therapy for Parkinson’s Disease. Mol Ther. 2018;26(2):550–567.
- Cole TA, Zhao H, Collier TJ, et al. Alpha-synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease. bioRxiv 830554. 2019. DOI:10.1101/830554
- Yahara A, Shrestha AR, Yamamoto T, et al. Amido-bridged nucleic acids (AmNAs): synthesis, duplex stability, nuclease resistance, and in vitro antisense potency. Chembiochem. 2012;13(17):2513–2516.
- Uehara T, Choong C, Nakamori M, et al. Amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides targeting α-synuclein as a novel therapy for Parkinson’s disease. Sci Rep. 2019;9:7567. DOI:10.1038/s41598-019-43772-9
- Zhang P, Park HJ, Zhang J, et al. Translation of the intrinsically disordered protein α-synuclein is inhibited by a small molecule targeting its structured mRNA. Proc Natl Acad Sci U S A. 2020;117(3):1457–1467.
- Mittal S, Bjørnevik K, Im DS, et al. β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson’s disease. Science. 2017;357(6354):891–898.
- Magistrelli L, Comi C. Beta2-Adrenoceptor agonists in Parkinson’s disease and other synucleinopathies. J Neuroimmune Pharmacol. 2020;15(1):74–81.
- Snead D, Eliezer D. Alpha-Synuclein function and dysfunction on cellular membranes. Exp Neurobiol. 2014;23(4):292–313.
- Wrasidlo W, Tsigelny IF, Price DL, et al. A de novo compound targeting α-synuclein improves deficits in models of Parkinson’s disease. Brain. 2016;139(12):3217–3236.
- Price DL, Koike MA, Khan A, et al. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson’s disease. Sci Rep. 2018;8:16165.
- Neuropore announces successful completion of phase I with its lead compound NPT200-11. [cited 2020 Apr 28]. Available from: https://www.neuropore.com/media/news/neuropore-therapies-completes-phase-1-clinical-trials6430.htm
- Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24(2):197–211.
- Holmqvist S, Chutna O, Bousset L, et al. Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta Neuropathol. 2014;128(6):805–820.
- Ulusoy A, Rusconi R, Pérez-Revuelta BI, et al. Caudo-rostral brain spreading of α-synuclein through vagal connections. EMBO Mol Med. 2013;5(7):1119–1127.
- Lionnet A, Leclair-Visonneau L, Neunlist M, et al. Does Parkinson’s disease start in the gut? Acta Neuropathol. 2018;135(1):1–12.
- Zasloff M, Adams AP, Beckerman B, et al. Squalamine as a broad-spectrum systemic antiviral agent with therapeutic potential [published correction appears in Proc Natl Acad Sci U S A. 2011 Nov 1;108(44):18186]. Proc Natl Acad Sci U S A. 2011;108(38):15978–15983.
- Perni M, Galvagnion C, Maltsev A, et al. A natural product inhibits the initiation of α-synuclein aggregation and suppresses its toxicity. Proc Natl Acad Sci USA. 2017;114(6):E1009–E1017.
- Perni M, Flagmeier P, Limbocker R, et al. Multistep inhibition of α-Synuclein aggregation and toxicity in vitro and in vivo by trodusquemine. ACS Chem Biol. 2018;13(8):2308–2319.
- Hauser RA, Sutherland D, Madrid JA, et al. Targeting neurons in the gastrointestinal tract to treat Parkinson’s disease. Clin Parkin Relat Dis. 2019;1:2–7.
- Wagner J, Ryazanov S, Leonov A, et al. Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease. Acta Neuropathol. 2013;125(6):795–813.
- Heras-Garvin A, Weckbecker D, Ryazanov S, et al. Anle138b modulates α-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy. Mov Disord. 2019;34(2):255–263.
- MODAG initiates first-in-human phase 1 clinical trial for anle138b. [cited 2020 Apr 28]. Available from: https://www.modag.net/images/20191218_MODAG_TrialStart_EN.pdf
- George S, Brundin P. Immunotherapy in Parkinson’s disease: micromanaging alpha-synuclein aggregation. J Parkinsons Dis. 2015;5(3):413–424.
- Masliah E, Rockenstein E, Adame A, et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson’s disease. Neuron. 2015;46(6):857–868.
- Mandler M, Valera E, Rockenstein E, et al., Next-generation active immunization approach for synucleinopathies: implications for Parkinson’s disease clinical trials. Acta Neuropathol. 2014;127(6):861–879.
- Volc D, Poewe W, Kutzelnigg A, et al. Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01 in patients with Parkinson’s disease: a randomised, single-blinded, phase 1 trial. Lancet Neurol. 2020;19:591–600.
- Wang CY, Finstad CL, Walfield AM, et al. Site-specific UBITh amyloid-beta vaccine for immunotherapy of Alzheimer’s disease. Vaccine. 2007;25(16):3041–3052.
- United neuroscience strengthens vaccine pipeline with novel immunotherapy for Parkinson’s disease. [cited 2020 Apr 28]. Available from: https://www.prnewswire.com/news-releases/united-neuroscience-strengthens-vaccine-pipeline-with-novel-immunotherapy-for-parkinsons-disease-300749220.html
- Davtyan H, Zagorski K, Petrushina I, et al. MultiTEP platform-based DNA vaccines for alpha-synucleinopathies: preclinical evaluation of immunogenicity and therapeutic potency. Neurobiol Aging. 2017;59:156–170.
- Games D, Valera E, Spencer B, et al. Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson’s disease-like models. J Neurosci. 2014;34(28):9441–9454.
- Jankovic J, Goodman I, Safirstein B, et al. Safety and tolerability of multiple ascending doses of PRX002/RG7935, an anti-α-synuclein monoclonal antibody, in patients with Parkinson disease: a randomized clinical trial. JAMA Neurol. 2018;75(10):1206–1214.
- Update on phase 2 PASADENA study of Prasinezumab (PRX002/RG7935) in Parkinson’s disease. [cited 2020 Jul 2]. Available from: http://ir.prothena.com/news-releases/news-release-details/update-phase-2-pasadena-study-prasinezumab-prx002rg7935
- Weihofen A, Liu Y, Arndt JW, et al. Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson’s disease models. Neurobiol Dis. 2019;124:276–288.
- Brys M, Fanning L, Hung S, et al. Randomized phase I clinical trial of anti-α-synuclein antibody BIIB054. Mov Disord. 2019;34(8):1154-1163. doi: 10.1002/mds.27738
- Schofield DJ, Irving L, Calo L, et al. Preclinical development of a high affinity α-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular α-synuclein and attenuate α-synuclein spreading in vivo. Neurobiol Dis. 2019;132:104582.
- Lindström V, Fagergvist T, Nordström E, et al. Immunotherapy targeting α-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] α-synuclein mice. Neurobiol Dis. 2014;69:134–143.
- Watts RJ, Dennis MS. Bispecific antibodies for delivery into the brain. Curr Opin Chem Biol. 2013;17(3):393–399.
- Derkinderen P, Rouaud T, Lebouvier T, et al. Parkinson disease: the enteric nervous system spills its guts. Neurology. 2011;77(19):1761–1767.
- Kanodia JS, Gadkar K, Bumbaca D, et al. Prospective design of anti-transferrin receptor bispecific antibodies for optimal delivery into the human brain CPT. Pharmacometrics Syst Pharmacol. 2016;5(5):283–291.
- Bothwell M. Recent advances in understanding neurotrophin signaling. F1000Res. 2016;5:F1000Faculty Rev–1885. Published 2016 Jul 28.
- Skaper SD, Walsh FS. Neurotrophic molecules: strategies for designing effective therapeutic molecules in neurodegeneration. Mol Cell Neurosci. 1998;12(4–5):179–193.
- Lim ST, Airavaara M, Harvey BK. Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS. Pharmacol Res. 2010;61(1):14–26.
- MimeTech pipeline. [cited 2020 Jul 2]. Available from: https://mimetech.eu/the-technology/pipeline/
- STATegics, Inc. Announces a second grant from The Michael J. Fox foundation for Parkinson's research. [cited 2020 Apr 28]. Available from: http://stategics.com/doc/2015-03-25_Press_Release_MJFF_2nd_Grant.pdf
- Minerva neurosciences pipeline. [cited 2020 Apr 28]. Available from: http://www.minervaneurosciences.com/innovation-pipeline/min-301/
- Clarke E, Sinclair L, Fletcher EJR, et al. TrkB agonist antibody delivery to the brain using a TfR1 specific BBB shuttle provides neuroprotection in a mouse model of Parkinson’s disease. bioRxiv. 2020. DOI:10.1101/2020.03.12.987313
- Neuronascent pipeline. [cited 2020 Apr 28]. Available from: https://neuronascent.com/rd-programs/parkinsons-disease/
- Genervon presents innovative CNS drug candidate at 2018 BIO CEO & investor conference. [cited 2020 Apr 28]. Available from https://www.genervon.com/pressreleases/genervon-at-bio-2018
- Ibáñez CF, Andressoo JO. Biology of GDNF and its receptors - relevance for disorders of the central nervous system. Neurobiol Dis. 2017;97(Pt B):80–89.
- Drinkut A, Tillack K, Meka DP, et al. Ret is essential to mediate GDNF’s neuroprotective and neuroregenerative effect in a Parkinson disease mouse model. Cell Death Dis. 2016;7(9):e2359.
- Kramer ER, Liss B. GDNF-Ret signaling in midbrain dopaminergic neurons and its implication for Parkinson disease. FEBS Lett. 2015;589(24Pt A):3760–3772.
- Hoffer BJ, Harvey B. Is GDNF beneficial in Parkinson disease? Nat Rev Neurol. 2011;7(11):600–602.
- Ai Y, Markesbery W, Zhang Z, et al. Intraputamenal infusion of GDNF in aged rhesus monkeys: distribution and dopaminergic effects. J Comp Neurol. 2003;461(2):250–261.
- Whone A, Luz M, Boca M, et al. Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson’s disease. Brain. 2019;142:512–525.
- Whone A, Boca M, Luz M, et al. Extended treatment with glial cell line-derived neurotrophic factor in Parkinson’s disease. J Parkinson’s Dis. 2019;9:301–313.
- Fu A, Zhou QH, Hui EK, et al. Intravenous treatment of experimental Parkinson’s disease in the mouse with an IgG-GDNF fusion protein that penetrates the blood-brain barrier. Brain Res. 2010;1352:208–213.
- Pardridge WM, Boado RJ. Pharmacokinetics and safety in Rhesus monkeys of a monoclonal antibody-GDNF fusion protein for targeted blood-brain barrier delivery. Pharm Res. 2009;26(10):2227–2236.
- Mahato AK, Kopra J, Renko JM, et al. Glial cell line-derived neurotrophic factor receptor rearranged during transfection agonist supports dopamine neurons in vitro and enhances dopamine release in vivo. Mov Disord. 2020;35(2):245–255.
- Sidorova YA, Bespalov MM, Wong AW, et al. A novel small molecule GDNF receptor RET agonist, BT13, promotes neurite growth from sensory neurons in vitro and attenuates experimental neuropathy in the rat. Front Pharmacol. 2017;8:365. Published 2017 Jun 21.
- Lindholm P, Voutilainen MH, Laurén J, et al. Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Nature. 2007;448(7149):73–77.
- Tang T, Li Y, Jiao Q, et al. Cerebral Dopamine Neurotrophic Factor: a potential therapeutic agent for Parkinson’s disease. Neurosci Bull. 2017;33(5):568–575.
- Garea-Rodríguez E, Eesmaa A, Lindholm P, et al. Comparative analysis of the effects of neurotrophic factors CDNF and GDNF in a nonhuman primate model of Parkinson’s disease. PLoS One. 2016;11(2):e0149776.
- Voutilainen MH, Bäck S, Peränen J, et al. Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson’s disease. Exp Neurol. 2011;228(1):99–108.
- Herantis pharma Plc announces topline results of Phase 1-2 CDNF trial. [cited 2020 Apr 28]. Avilable from: https://herantis.com/press_releases/herantis-pharma-plc-announces-topline-results-of-phase-1-2-cdnf-trial/
- Gantner CW, de Luzy IR, Kauhausen JA, et al. Viral delivery of gdnf promotes functional integration of human stem cell grafts in Parkinson’s disease. Cell Stem Cell. 2020;26(4):511–526.e5.
- Petrova P, Raibekas A, Pevsner J, et al. MANF: a new mesencephalic, astrocyte-derived neurotrophic factor with selectivity for dopaminergic neurons. J Mol Neurosci. 2003;20(2):173–188.
- Voutilainen M, Bäck S, Pörsti E, et al. Mesencephalic astrocyte-derived neurotrophic factor is neurorestorative in rat model of Parkinson’s disease. J Neurosci. 2009;29(30):9651–9659.
- Zhang Z, Shen Y, Luo H, et al. MANF protects dopamine neurons and locomotion defects from a human α-synuclein induced Parkinson’s disease model in C. elegans by regulating ER stress and autophagy pathways. Exp Neurol. 2018;308:59–71.
- Fried W. Erythropoietin and erythropoiesis. Exp Hematol. 2009;37(9):1007–1015.
- Marti HH, Wenger RH, Rivas LA, et al. Erythropoietin gene expression in human, monkey and murine brain. Eur J Neurosci. 1996;8(4):666–676.
- Rey F, Balsari A, Giallongo T, et al. Erythropoietin as a neuroprotective molecule: an overview of its therapeutic potential in neurodegenerative diseases. ASN Neuro. 2019;11:1759091419871420.
- Noguchi CT, Asavaritikrai P, Teng R, et al. Role of erythropoietin in the brain. Crit Rev Oncol Hematol. 2007;64(2):159–171.
- Puskovic V, Wolfe D, Wechuck J, et al. HSV-mediated delivery of erythropoietin restores dopaminergic function in MPTP-treated mice. Mol Ther. 2006;14(5):710–715.
- Zhou QH, Hui EK, Lu JZ, et al. Brain penetrating IgG-erythropoietin fusion protein is neuroprotective following intravenous treatment in Parkinson’s disease in the mouse. Brain Res. 2011;1382:315–320.
- Hyman C, Hofer M, Barde YA, et al. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature. 1991;350(6315):230–232.
- Bathina S, Das UN. Brain-derived neurotrophic factor and its clinical implications 1. Arch Med Sci. 2015;11(6):1164–1178.
- Mogi M, Togari A, Kondo T, et al. Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson’s disease. Neurosci Lett. 1999;23;270(1):45–48.
- Scalzo P, Kümmer A, Bretas TL, et al. Serum levels of brain-derived neurotrophic factor correlate with motor impairment in Parkinson’s disease. J Neurol. 2010;257(4):540–545.
- Kishimoto Y, Johnson J, Fang W, et al. A mitochondrial uncoupler prodrug protects dopaminergic neurons and improves functional outcome in a mouse model of Parkinson’s disease. Neurobiol Aging. 2020;85:123–130.
- Li N, Ragheb K, Lawler G, et al. Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production. J Biol Chem. 2003;278(10):8516–8525.
- Shimoke K, Kudo M, Ikeuchi T. MPTP-induced reactive oxygen species promote cell death through a gradual activation of caspase-3 without expression of GRP78/Bip as a preventive measure against ER stress in PC12 cells. Life Sci. 2003;73(5):581–593.
- Kowall NW, Hantraye P, Brouillet E, et al. MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons. Neuroreport. 2000;11(1):211–213.
- Vila M, Vukosavic S, Jackson-Lewis V, et al. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J Neurochem. 2000;74(2):721–729.
- Sherer TB, Kim JH, Betarbet R, et al. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp Neurol. 2003;179(1):9–16.
- Perier C, Vila M. Mitochondrial biology and Parkinson’s disease. Cold Spring Harb Perspect Med. 2012;2(2):a009332.
- GliaCure pipeline. [cited 2020 Apr 28]. Available from: https://gliacure.com/about-glia-cure/our-approach/
- Encefa. Website. [cited 2020 Apr 28]. Available from: https://www.encefa.com/our-antibodies/basis-of-our-mechanism-of-action/
- Neuropore Therapies pipeline. [cited 2020 Apr 28]. Available from: https://www.neuropore.com/programs/pipeline.htm
- Plex pharmaceuticals awarded $670,865 grant funding from The Michael J. Fox foundation for Parkinson’s research. [cited 2020 Apr 28]. Available from: https://www.prnewswire.com/news-releases/plex-pharmaceuticals-awarded-670865-grant-funding-from-the-michael-j-fox-foundation-for-parkinsons-research-300298184.html
- Genkyotex pipeline. [cited 2020 Apr 28]. Available from: https://www.genkyotex.com/en/pipeline/preclinical-nox1-program
- Mission therapeutics pipeline. [cited 2020 Apr 28]. Available from: https://missiontherapeutics.com/pipeline/
- Aranda pharmaceuticals pipeline. [cited 2020 Apr 28]. Available from: http://arandapharma.com/research-development
- PK biosciences pipeline. [cited 2020 Apr 28]. Available from: http://www.pkbio.com/product-pipeline.html
- Gordon R, Albornoz EA, Christie DC, et al. Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice. Sci Transl Med. 2018;10(465):eaah4066.
- Collaborative medicinal development pipeline. [cited 2020 Apr 28]. Available from: https://colmeddev.com/pipeline/
- Med-life pipeline. [cited 2020 Apr 28]. Available from: https://med-life.ca/parkinsons
- Neuroene therapeutics. [cited 2020 Apr 28]. Available from: https://www.neuroenetherapeutics.com/
- Khondrion. website. [cited 2020 Apr 28]. Available from: https://www.khondrion.com/rd/
- New world lab pipeline. [cited 2020 Apr 28]. Available from: https://nwl.net/en/cell-regeneration-peptides/
- Zhittya medical innovation series, No. 016: [updated 2020 January 3; cited 2020 Apr 28]. Available from: https://nebula.wsimg.com/3cef08d3854b22db8cbb8d54bfda8980?AccessKeyId=571F68CFB2C858978E25&disposition=0&alloworigin=1
- Guangzhou magpie pharmaceuticals pipeline. [cited 2020 Apr 28]. Available from: http://magpiepharma.com/Productsshow.asp?id=23
- Pipeline HP. [cited 2020 Apr 28]. Available from: http://www.hanmipharm.com/ehanmi/handler/Rnd-FocusedPipelineB
- CytRx corporation highlights updated arimoclomol milestone guidance provided by licensee Orphazyme A/S. [cited 2020 Apr 28]. Available from: https://www.ptcommunity.com/wire/cytrx-corporation-highlights-updated-arimoclomol-milestone-guidance-provided-licensee-orphazyme
- DermaXon pipeline. [cited 2020 Apr 28]. Available from: https://dermaxon.com/pipeline/
- Mitoconix Bio hits $20M series A for neurodegenerative R&D. [cited 2020 Apr 28]. Available from: https://www.fiercebiotech.com/biotech/mitoconix-bio-hits-20m-series-a-for-neurodegenerative-r-d
- Retotrope pipeline. [cited 2020 Apr 28]. Available from: https://www.retrotope.com/other-preclinical-models
- Shijiazhuang Yiling pharmaceutical Co., Ltd. Fenlean (flz) crystal g form, preparation method, and composition and use there of. WO2019011350
- Inflazome progresses two drugs into clinical trials. [cited 2020 Apr 28]. Available from: http://www.inflazome.com/news/32
- GNT pharma pipeline. [cited 2020 Apr 28]. Available from: http://gntpharma.com/en/pipeline/aad-2004-neurological-diseases/
- Alector initiates first-in-human dosing in phase 1 study of AL101 for the treatment of neurodegenerative diseases. [cited 2020 Apr 28]. Available from: https://www.globenewswire.com/news-release/2020/01/06/1966480/0/en/Alector-Initiates-First-in-Human-Dosing-in-Phase-1-Study-of-AL101-for-the-Treatment-of-Neurodegenerative-Diseases.html
- Gendelman HE, Zhang Y, Santamaria P, et al. Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson’s disease trial. NPJ Parkinsons Dis. 2017;3:10.
- Martin-Bastida A, Ward RJ, Newbould R, et al. Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson’s disease. Sci Rep. 2017;7:1398.
- Safety and efficacy of liraglutide in Parkinson’s disease. [cited 2020 Apr 28]. Available from: https://clinicaltrials.gov/ct2/show/NCT02953665
- Study to evaluate the effect of lixisenatide in patient with Parkinson’s disease (LixiPark). [cited 2020 Apr 28]. Available from: https://clinicaltrials.gov/ct2/show/NCT03439943
- A clinical study of NLY01 in patient’s with Early Parkinson’s disease. [cited 2020 Apr 28]. Available from: https://clinicaltrials.gov/ct2/show/NCT04154072
- Clene nanomedicine pipeline. [cited 2020 Apr 28]. Available from: https://clene.com/pipeline/
- Alkahest initiates a phase 2 clinical trial of AKST4290 in Parkinson’s disease with funding from The Michael J. Fox Foundation. [cited 2020 Apr 28]. Available from: http://www.globenewswire.com/news-release/2020/02/04/1979397/0/en/Alkahest-Initiates-a-Phase-2-Clinical-Trial-of-AKST4290-in-Parkinson-s-Disease-with-Funding-from-The-Michael-J-Fox-Foundation.html
- Pipeline SD. [cited 2020 Apr 28]. Available from: https://www.ds-pharma.com/rd/clinical/pipeline.html
- Deshmukh P, Unni S, Krishnappa G, et al. The Keap1–Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases. Biophys Rev. 2016;9(1):41–56.
- Wang B, Liu Q, Shan H, et al. Nrf2 inducer and cncC overexpression attenuates neurodegeneration due to α-synuclein in Drosophila. Biochem Cell Biol. 2015;93(4):351–358.
- Kim S, Indu Viswanath AN, Park JH, et al. Nrf2 activator via interference of Nrf2-Keap1 interaction has antioxidant and anti-inflammatory properties in Parkinson’s disease animal model. Neuropharmacology. 2020;167:107989.
- University of Sheffield, Pamela SHAW, Richard Mead, Adrian Higginbottom, et al. Therapeutics for neurological disorders. WO2010046710
- Das S C, Ramakrishna S, KS K. Critical roles of deubiquitinating enzymes in the nervous system and neurodegenerative disorders. Mol Cells. 2020;43(3):203‐214.
- Chakraborty J, von Stockum S, Marchesan E, et al. USP14 inhibition corrects an in vivo model of impaired mitophagy. EMBO Mol Med. 2018;10(11):e9014.
- Cunningham CN, Baughman JM, Phu L, et al. USP30 and parkin homeostatically regulate atypical ubiquitin chains on mitochondria. Nat Cell Biol. 2015;17(2):160‐169.
- Jeong JS, Piao Y, Kang S, et al. Triple herbal extract DA-9805 exerts a neuroprotective effect via amelioration of mitochondrial damage in experimental models of Parkinson’s disease. Sci Rep. 2018;8(1):15953.
- Yu C, Kim B, Kim E. FAF1 mediates regulated necrosis through PARP1 activation upon oxidative stress leading to dopaminergic neurodegeneration. Cell Death Differ. 2016;23(11):1873–1885.
- Shin W, Lim KS, Kim MK, et al. A first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 (FAS-associated factor 1 inhibitor), a drug for Parkinson’s disease, in healthy volunteers. Drug Des Devel Ther. 2019;13:1011–1022.
- Ghosh A, Tyson T, George S, et al. Mitochondrial pyruvate carrier regulates autophagy, inflammation and neurodegeneration in experimental models of Parkinson’s disease. Sci Transl Med. 2016;8(368):368ra174.
- Kempuraj D, Thangavel R, Natteru PA, et al. Neuroinflammation induces neurodegeneration. J Neurol Neurosurg Spine. 2016;1(1):1003.
- Athauda D, Foltynie T. The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson’s disease: mechanisms of action. Drug Disc Today. 2016;21(5):802–818.
- Athauda D, Maclagan K, Skene SS, et al. Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10103):1664–1675.
- Chen S, Yu S, Li Y, et al. Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson’s disease. Sci Rep. 2018;8:10722.
- Ikeda-Matsuo Y, Miyata H, Mizoguchi T, et al. Microsomal prostaglandin E synthase-1 is a critical factor in dopaminergic neurodegeneration in Parkinson’s disease. Neurobiol Dis. 2019;124:81–92.
- Olson KE, Kosloski-Bilek LM, Anderson KM, et al. Selective VIP receptor agonists facilitate immune transformation for dopaminergic neuroprotection in MPTP-intoxicated Mice. J Neurosci. 2015;35(50):16463–16478.
- Mosley RL, Lu Y, Olson KE, et al. A synthetic agonist to vasoactive intestinal peptide receptor-2 induces regulatory T cell neuroprotective activities in models of Parkinson’s disease. Front Cell Neurosci. 2019;13:421. Published 2019 Sep 18.
- Delgado M, Ganea D. Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson’s disease by blocking microglial activation. Faseb J. 2003;17(8):944–946.
- Rea K, Dinan TG, Cryan JF. The microbiome: A key regulator of stress and neuroinflammation. Neurobiol Stress. 2016;4:23–33. Published 2016 Mar 4.
- Yuille S, Reichardt N, Panda S, et al. Human gut bacteria as potent class I histone deacetylase inhibitors in vitro through production of butyric acid and valeric acid. PLoS ONE. 2018;13(7):e0201073.
- Ahmed S, Busetti A, Fotiadou P, et al. In vitro characterization of gut microbiota-derived bacterial strains with neuroprotective properties. Front Cell Neurosci. 2019;13:402. Published 2019 Sep 20.
- Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science. 1997;276(5321):2045–2047.
- Lunati A, Lesage S, Brice A. The genetic landscape of Parkinson’s disease. Rev Neurol (Paris). 2018;174(9):628–643.
- NTRC website. [cited 2020 Apr 28]. Available from: https://www.ntrc.nl/projects/parkinsons-disease/
- Alectos pipeline. [cited 2020 Apr 28]. Available from: http://alectos.com/content/pipeline/
- The Michael J. Fox foundation and imago pharmaceuticals partner to advance use of research tools to speed Parkinson’s research. [cited 2020 Apr 28]. Available from: https://www.michaeljfox.org/publication/michael-j-fox-foundation-and-imago-pharmaceuticals-partner-advance-use-research-tools
- Amicus therapeutics presents preclinical studies of chaperone AT3375 for Gaucher disease. [cited 2020 Apr 29]. Available from: https://ir.amicusrx.com/news-releases/news-release-details/amicus-therapeutics-presents-preclinical-studies-chaperone
- Sardi SP, Viel C, Clarke J, et al. Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models. Proc Natl Acad Sci U S A. 2017;114(10):2699‐2704.
- PTC Therapeutics Pipeline. [cited 2020 Apr 29]. Available from: https://www.ptcbio.com/our-pipeline/portfolio-pipeline/
- Oxyrane Pipeline. [cited 2020 Apr 29]. Available from: https://www.oxyrane.com/#programs
- ESCAPE bio announces excellent safety and tolerability in phase 1 study of oral S1P5 receptor agonist ESB1609. [cited 2020 Jul 28]. Available from: https://www.escapebio.com/press-releases/escape-bio-announces-excellent-safety-and-tolerability-in-phase-1-study-of-oral-s1p5-receptor-agonist-esb1609/
- NeurAxon Pipeline. [cited 2020 Apr 29]. Available from: http://www.neuraxon.com/pipeline.html
- Ariga H, Takahashi-Niki K, Kato I, et al. Neuroprotective function of DJ-1 in Parkinson’s disease. Oxid Med Cell Longev. 2013;2013:683920.
- Bonifati V, Rizzu P, van Baren MJ, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science. 2003;299(5604):256–259.
- Cantabio pharmaceuticals to present latest positive in vivo results from its DJ-1 targeting small molecule drug development program for Parkinson’s disease at the Milner therapeutics symposium at the university of Cambridge, UK. [cited 2020 Jul 28]. Available from: https://www.cantabio.com/news-media/press-releases/detail/29/cantabio-pharmaceuticals-to-present-latest-positive-in-vivo
- Valente EM, Abou-Sleiman PM, Caputo V, et al. Hereditary early-onset Parkinson’s disease caused by mutations in PINK1. Science. 2004;304(5674):1158–1160.
- Ahlskog JE. Parkin and PINK1 parkinsonism may represent nigral mitochondrial cytopathies distinct from Lewy body Parkinson’s disease. Parkinsonism Relat Disord. 2009;15(10):721–727.
- Mehdi SJ, Rosas-Hernandez H, Cuevas E, et al. Protein Kinases and Parkinson’s Disease. Int J Mol Sci. 2016;17(9):1585.
- Beasley SA, Hristova VA, Shaw GS. Structure of the Parkin in-between-ring domain provides insights for E3-ligase dysfunction in autosomal recessive Parkinson’s disease. Proc Natl Acad Sci U S A. 2007;104(9):3095–3100.
- Spratt DE, Martinez-Torres RJ, Noh YJ, et al. A molecular explanation for the recessive nature of parkin-linked Parkinson’s disease. Nat Commun. 2013;4:1983.
- Benskey M, Lee KY, Parikh K, et al. Sustained resistance to acute MPTP toxicity by hypothalamic dopamine neurons following chronic neurotoxicant exposure is associated with sustained up-regulation of parkin protein. Neurotoxicology. 2013;37:144–153.
- Hertz NT, Berthet A, Sos ML, et al. A neo-substrate that amplifies catalytic activity of Parkinson’s-disease-related kinase PINK1. Cell. 2003;154(4):737–747.
- Duong T, Kim J, Ruley HE, et al. Cell-permeable parkin proteins suppress Parkinson disease-associated phenotypes in cultured cells and animals [published correction appears in PLoS One. 2014;9(12):e116242]. PLoS One. 2014;9(7):e102517. Published 2014 Jul 14.
- Zunke F, Moise AC, Belur NR, et al. Reversible Conformational Conversion of α-Synuclein into Toxic Assemblies by Glucosylceramide. Neuron. 2018;97(1):92–107.e10.
- Brockmann K, Hilker R, Pilatus U, et al. GBA-associated PD. Neurodegeneration, altered membrane metabolism, and lack of energy failure. Neurology. 2012;79(3):213–220.
- Liu G, Boot B, Locascio JJ, et al. Specifically neuropathic Gaucher’s mutations accelerate cognitive decline in Parkinson’s. Ann Neurol. 2016;80(5):674–685.
- Fischer T, Sardi SP, Peterschmitt MJ. Evaluation of Glucosylceramide Synthase (GCS) Inhibition for GBA-Associated Parkinson’s Disease. Neurology. 2018;90(15 Supplement):P3.051.
- Fischer T, Gasser T, Isaacson S, et al. Safety, tolerability and pharmacokinetics of oral venglustat in Parkinson’s disease patients with a GBA mutation. Neurology. 2019;92(15 Supplement):S4.002.
- Sidransky E, Arkadir D, Bauer P, et al. Substrate reduction therapy for GBA1-associated Parkinsonism: are we betting on the wrong mouse? Mov Disord. 2020;35(2):228–230.
- Mazzulli JR, Zunke F, Tsunemi T, et al. Activation of β-Glucocerebrosidase reduces pathological α-Synuclein and restores lysosomal function in Parkinson’s patient midbrain neurons. J Neurosci. 2016;36(29):7693–7706.
- Schneider SA, Alcalay RN. Precision medicine in Parkinson’s disease: emerging treatments for genetic Parkinson’s disease. J Neurol. 2020;267(3):860–869.
- Schipper HM, Liberman A, Stopa EG. Neural heme oxygenase-1 expression in idiopathic Parkinson’s disease. Exp Neurol. 1998;150(1):60–68.
- Cuadrado A, Rojo AI. Heme oxygenase-1 as a therapeutic target in neurodegenerative diseases and brain infections. Curr Pharm Des. 2008;14(5):429–442.
- Ayuso P, Martínez C, Pastor P, et al. An association study between Heme oxygenase-1 genetic variants and Parkinson’s disease. Front Cell Neurosci. 2014;8:298. Published 2014 Sep 24.
- Azymus therapeutics pipeline. [cited 2020 Apr 29]. Available from: https://azymustherapeutics.com/platform/Last
- Suzhou Yabao pharmaceutical R&D CO., Ltd. Innovative Pharmaceutical R&D in China: Status and Trends; [cited 2020 Jul 28]. Available from: https://apac-asia.com/images/achievements/pdf/7th/C_Drug/D-04_Innovative.pdf.
- E-scape bio pipeline. [cited 2020 Apr]. Available from: http://www.e-scapebio.com/pipeline/index.php
- Vernalis Research Pipeline. [cited 2020 April 29]. Available from: https://www.vernalis.com/portfolio-items/design-of-leucine-rich-repeat-kinase-2-lrrk2/Last
- Imago Pharma. [cited 2020 April 29]. Available from: http://www.imago-pharma.com/our-approach.html
- Lead discovery center pipeline. [cited 2020 April 29]. Available from: https://www.lead-discovery.de/en/portfolio/?d1=3-&d2=all&x1=false&x2=false&x3=false#result
- Cerevel Pipeline. [cited 2020 April 29]. Available from: https://www.cerevel.com/what-next
- Neurotrope pipeline. [cited 2020 April 29]. Available from: https://neurotrope.com/#pipeline
- Kline EM, Butkovich LM, Bradner JM, et al. The second generation mixed lineage kinase-3 (MLK3) inhibitor CLFB-1134 protects against neurotoxin-induced nigral dopaminergic neuron loss. Exp Neurol. 2019;318:157–164.
- IkT-148009 for Parkinson’s disease and GI complications of Parkinson’s patients. [cited 2020 April 29]. Available from: https://www.inhibikase.com/pipeline/ikt-148009-for-parkinsons-disease/
- A new approach to R&D at GSK. cited 2020 Apr 29. Available from: https://www.gsk.com/media/5041/rd-update-slides-hal-barron.pdf
- Arrien pharma pipeline. [cited 2020 April]. Available from: http://www.arrienpharma.com/parkinsons.html
- Oncodesign pipeline. [cited 2020 Apr 29]. Available from: https://www.oncodesign.com/en/partnership/kinase-inhibitor-development-programs
- Imago pharmaceuticals. [cited 2020 Apr 29]. Available from: http://www.imago-pharma.com/our-programs.html
- PhorMed Inc. [cited 2020 Apr 29]. Available from: https://www.phormed.com/science/neurology/
- 1STBIO pipeline. [cited 2020 Apr 29]. Available from: http://www.1stbio.com/#research
- Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004;44(4):601–607.
- Healy DG, Falchi M, O’Sullivan SS, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: a case-control study. Lancet Neurol. 2008;7(7):583–590.
- Lesage S, Dürr A, Tazir M, et al. LRRK2 G2019S as a cause of Parkinson’s disease in North African Arabs. N Engl J Med. 2006;354(4):422–423.
- Li J-Q TL. The role of the LRRK2 gene in Parkinsonism. Mol Neurodegener. 2014;9:47.
- Estrada AA, Liu X, Baker-Glenn C, et al. Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. J Med Chem. 2012;55(22):9416–9433.
- Fuji RN, Flagella M, Baca M, et al., Effect of selective LRRK2 kinase inhibition on nonhuman primate lung. Sci Transl Med. 2015;7(273):273ra15.
- Denali therapeutics announces positive clinical results from LRRK2 inhibitor program for Parkinson’s disease. [cited 2020 Apr 28] Available from: http://investors.denalitherapeutics.com/news-releases/news-release-details/denali-therapeutics-announces-positive-clinical-results-lrrk2#ir-pages
- Denali therapeutics announces broad pipeline progress including positive results from its LRRK2 program for Parkinson’s disease. [cited 2020 Apr 28]. Available from: http://investors.denalitherapeutics.com/news-releases/news-release-details/denali-therapeutics-announces-broad-pipeline-progress-including
- Zhao HT, John N, Delic V, et al. LRRK2 antisense oligonucleotides ameliorate α-synuclein inclusion formation in a Parkinson’s disease mouse model. Mol Ther Nucleic Acids. 2017;8:508–519.
- Brahmachari S, Karuppagounder SS, Ge P, et al. c-Abl and Parkinson’s disease: mechanisms and therapeutic potential. J Parkinsons Dis. 2017;7(4):589–601.
- Brahmachari S, Ge P, Lee SH, et al. Activation of tyrosine kinase c-Abl contributes to α-synuclein-induced neurodegeneration. J Clin Invest. 2016;126(8):2970–2988.
- Karuppagounder SS, Brahmachari S, Lee Y, et al. The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson’s disease. Sci Rep. 2014;4:4874. Published 2014 May 2.
- Pagan F, Hebron M, Valadez EH, et al. Nilotinib effects in Parkinson’s disease and dementia with Lewy bodies. J Parkinsons Dis. 2016;6(3):503–517.
- Pagan FL, Hebron ML, Wilmarth B, et al. Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson’s disease. Pharmacol Res Perspect. 2019;7(2):e00470. Published 2019 Mar 12.
- Pagan FL, Hebron ML, Wilmarth B, et al. Nilotinib effects on safety, tolerability, and potential biomarkers in Parkinson disease: a phase 2 randomized clinical trial. JAMA Neurol. 2019;77(3):309–317.
- Simuni T, Fiske B, Merchant K, et al. Nilotinib in patients with advanced Parkinson’s disease: a randomised phase 2A study (NILO-PD). medRxiv. 2020. DOI:10.1101/2020.05.11.20093146
- Lee S, Kim S, Park YJ, et al. The c-Abl inhibitor, Radotinib HCl, is neuroprotective in a preclinical Parkinson’s disease mouse model. Hum Mol Genet. 2018;27(13):2344–2356.
- Sun pharma advanced research company pipeline. [cited 2020 Apr 28]. Available from: https://www.sparc.life/research-programs/scc-138
- Goldfine A, Faulkner R, Sadashivam V, et al. Results of a phase 1 dose-ranging trial, and design of a phase 2 trial, of K0706, a novel C-Abl tyrosine kinase inhibitor for Parkinson’s disease. Neurology. 2019;92(15 Supplement):P2.8–047.
- Hunot S, Vila M, Teismann P, et al. JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson’s disease. Proc Natl Acad Sci U S A. 2004;101(2):665–670.
- Pan J, Qian J, Zhang Y, et al. Small peptide inhibitor of JNKs protects against MPTP-induced nigral dopaminergic injury via inhibiting the JNK-signaling pathway. Lab Invest. 2010;90(2):156–167.
- Parkinson study group PRECEPT investigators. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology. 2007;69(15):1480–1490.
- Probst GD, Bowers S, Sealy JM, et al. Highly selective c-Jun N-terminal kinase (JNK) 2 and 3 inhibitors with in vitro CNS-like pharmacokinetic properties prevent neurodegeneration. Bioorg Med Chem Lett. 2011;21(1):315–319.
- Decressac M, Björklund A. mTOR inhibition alleviates L-DOPA-induced dyskinesia in parkinsonian rats. J Parkinsons Dis. 2013;3(1):13–17.
- resTORbio announces initiation of phase 1b/2a trial of RTB101 in Parkinson’s disease. [cited 2020 Apr 28] Available from: https://www.globenewswire.com/news-release/2019/04/02/1795088/0/en/resTORbio-Announces-Initiation-of-Phase-1b-2a-Trial-of-RTB101-in-Parkinson-s-Disease.html
- Stecher B. [cited 2019 May 24]. The Futile Hunt for Disease Modifying Therapies. J Park Dis. Available from https://www.journalofparkinsonsdisease.com/blog/stecher/futile-hunt-disease-modifying-therapies
- PDTrialTracker.info. [cited 2020 Apr 20]. Available from: http://www.pdtrialtracker.info/
- LeWitt PA, Lipsman N, Kordower JH. Focused ultrasound opening of the blood-brain barrier for treatment of Parkinson’s disease. Mov Disord. 2019;34(9):1274–1278.
- Kordower JH, Bjorklund A. Trophic factor gene therapy for Parkinson’s disease. Mov Disord. 2013;28(1):96–109.
- Olanow CW, Kieburtz K. Defining disease-modifying therapies for PD–a road map for moving forward. Mov Disord. 2010;25(12):1774–1779.
- Zeissler ML, Li V, Parmar MKB. Is It Possible to Conduct a Multi-Arm Multi-Stage Platform Trial in Parkinson's Disease: Lessons Learned from Other Neurodegenerative Disorders and Cancer. J Parkinsons Dis. 2020;10(2):413-428. doi: 10.3233/JPD-191856
- Kim S, Kwon SH, Kam TI, et al. Transneuronal propagation of pathologic α-synuclein from the gut to the brain models Parkinson’s disease. Neuron. 2019;103(4):627–641.e7.
- Nuber S, Rajsombath M, Minakaki G, et al. Abrogating native α-Synuclein tetramers in Mice causes a L-DOPA-responsive motor syndrome closely resembling Parkinson’s disease. Neuron. 2018;100(1):75–90.e5.
- Di Maio R, Hoffman EK, Rocha EM, et al. LRRK2 activation in idiopathic Parkinson’s disease. Sci Transl Med. 2018;10(451):eaar5429.
- Mullin S, Smith L, Lee K, et al. Ambroxol for the treatment of patients with Parkinson disease with and without glucocerebrosidase gene mutations: a nonrandomized, noncontrolled trial. JAMA Neurol. 2020;77(4):427–434.
- Baptista MAS, Merchant K, Barrett T, et al. LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits. Sci Transl Med. 2020;12(540):eaav0820.